Biopharmaceutical News and Research

RSS

FUJIFILM Irvine Scientific launches Sterile Express Media Service

FUJIFILM Irvine Scientific, Inc., today announced the launch of Sterile Express Media Service (SEMS), for small-scale, rapid production of non-GMP media tested for sterility.

4 Dec 2020

Nanomedicine's giant step into the fight against the COVID-19

A recent editorial in Nature Nanotechnology discusses the enormous feat of scientific innovation, with messenger RNA (mRNA)-based vaccines developed to deliver the gene sequence of specific SARS-CoV-2 viral proteins into host cells using nanotechnology platforms.

1 Dec 2020

Marinomed plans a clinical trial with Carragelose nasal spray as COVID-19 prophylaxis

Marinomed Biotech AG, a globally operating biopharmaceutical company, is pleased to announce today that the Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID).

30 Nov 2020

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.

25 Nov 2020

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer is poised for clinical testing to begin in December.

25 Nov 2020

Marinomed to initiate clinical trial with Carragelose for preventing COVID19 in frontline healthcare staff

Marinomed Biotech AG, a globally operating biopharmaceutical company, announced today plans to initiate a Phase IV clinical trial with Carragelose (iota-carrageenan).

23 Nov 2020

Oxford University and AstraZeneca release their COVID-19 vaccine results

AstraZeneca and the University of Oxford have just released their results from its interim analysis of AZD1222, a vaccine being trialed to prevent COVID-19.

From AstraZeneca 23 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

Promising new compounds to potentially treat novel coronaviruses identified

Researchers at the University of Maryland School of Medicine and School of Pharmacy have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19.

15 Nov 2020

PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a leading gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.

From PhoreMost 10 Nov 2020

Research describes novel molecules designed to treat or prevent COVID-19 infection

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel molecules designed to treat or prevent infection by the virus that causes COVID-19, SARS-CoV-2.

6 Nov 2020

Remdesivir metabolite GS-441524 inhibits SARS CoV-2 in mouse model, finds study

This new study titled, "Remdesivir Metabolite GS-441524 Efficiently Inhibits SARS-CoV-2 Infection in Mouse Model," was released online as a preprint on the bioRxiv* server, prior to undergoing the peer-review process.

2 Nov 2020

Thermo Fisher Scientific and Symphogen extend collaboration to boost drug discovery and development

Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company, Servier, announce the extension of a strategic collaboration to deliver industry-proven, innovative characterization and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.

From Thermo Fisher Scientific Inc. 2 Nov 2020

McLean Hospital joins public-private partnership to find cure for schizophrenia

In September, McLean Hospital joined the National Institutes of Health, the U.S. Food and Drug Administration, and several public and private organizations to find early therapeutic interventions for people at risk for schizophrenia.

29 Oct 2020

Advancements in research on cancer signal transduction and treatment

Cancer is driven by numerous genetic and epigenetic changes occurring at the cellular level. These changes drive normal cells to proliferate and escape processes that usually regulate their survival and migration.

27 Oct 2020

Monoclonal Antibodies: Discovery, Characterization and Challenges

In this interview, News-Medical talks to David Apiyo, a senior manager of applications at Sartorius AG, about monoclonal antibody development and characterization.

22 Oct 2020

New inhaled treatment may lead to self-administered therapy for COVID-19

An inhaled treatment against the SARS-CoV-2 virus may lead to a future self-administered therapy for COVID-19, the pandemic that has killed more than 1 million people worldwide.

20 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses - including several that distinguish it from other COVID-19 vaccine approaches - according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

Genetic risk scoring of lipoprotein(a) can predict risk of atherosclerotic cardiovascular disease

Elevated levels of a little-known lipoprotein in the blood that may put people at high risk of cardiovascular disease can be as accurately detected by genetic testing as by conventional laboratory measurement, researchers at Massachusetts General Hospital (MGH) have found.

6 Oct 2020